Key Insights

Multi-Phase Analytics Suite

Environment:
Env: Fused Risk & Spend Clinical Pharmacy Coding What-If

Key Insights

Actionable findings from population analysis

Analysis Year:
View:
Active Filters Year: View:
M1 Claims: M2 Clinical: M3 Rx:

Insights partially unavailable

Data freshness:
Loading insights...

Key Findings

No findings available for this year. Check data freshness or try another year.

Risk Alerts

Total Members

in analysis population

Total Cost

$

medical reimbursement

Avg Cost/Member

$

per member per year

Risk Stratification Pyramid

Rising Risk Snapshot (baseline cost floor applied)

Rising members

Avg pct change

Total cost increase

$

Beneficiary Prior Cost Current Cost Change Comorbidity
No rising-risk members meet the baseline thresholds.

Page of

Baseline floor applied to avoid low-cost noise; showing paged results from top 50.

Predicted High-Cost (Next-Year Proxy)

Total candidates

High band members

Avg risk score

Beneficiary Risk Score Band Pred Cost Band Current Cost Comorbidity
No predicted candidates available.

Page of

Heuristic score blends current cost z-score (60%) and comorbidity load (40%).

Multi-Modal Fusion Coverage

Linked members

Rx linkage rate

Polypharmacy high rate

Condition Prevalence (Fused)

  • Diabetes:
  • Hypertension:
  • CHF:
  • COPD:

Match Quality Breakdown

Stratum Members Avg Expense Avg Encounters
No fusion data available.

Rx Adherence (Phase 2.5)

Member Class PDC Paid

Encounter Intensity (Phase 2)

Patient Total IP ED OP Tier

Therapy Gaps (Condition → Missing Therapy)

Member Condition Gap Severity

Fused Risk Candidates

Member Score Cost Z Comorbidity PDC Util Tier

Condition Cost Impact (Comorbidity-Adjusted)

Condition Prevalence Avg Cost With Avg Cost Without Adjusted Impact Multiplier

* Adjusted impact controls for comorbidity overlap. Negative values indicate condition is associated with lower costs when controlling for other factors.

High-Cost Condition Combinations

No high-cost combinations detected for this year.

Cost Concentration (Pareto Analysis)

costs from top 1%

costs from top 5%

costs from top 20%

Geographic Variation

Mean Avg Cost

CV

Min Avg Cost

Max Avg Cost

Highest Cost States

No high-cost outliers detected.

Lowest Cost States

No low-cost outliers detected.

Year-over-Year Trends

Year Total Cost Avg Cost Members
No trend data available.

Top Opportunities

Therapy Gap

Low Adherence

High-Risk Cohort

Fused cost + adherence + utilization

Data Quality Note

Costs shown use dim_beneficiary.total_medreimb as source of truth. Carrier claims (~33% of costs) are not included in claim-level detail. See DATA_QUALITY_REPORT.md for full documentation of limitations.

Loading...